Erie Times-News reports rising GLP-1 costs are pushing some Pennsylvania school districts to reconsider covering the drugs for employees.
Recap by typeshit. Full story at Erie Times-News.
Canada is one of the first big markets where semaglutide goes off patent. IQVIA plans ongoing updates on pricing, coverage and generic uptake.
The estimate, shared by M Mohan, starts from about $141 billion in 2025, with North America holding roughly 62% and semaglutide and tirzepatide leading.
The Medicare GLP-1 Bridge pilot runs July 2026 through 2027, covering FDA-approved pills and shots with no deductible for eligible Part D enrollees.
The two drugs brought in $14.9 billion of Lilly's $23.0 billion fiscal Q2 revenue while US prices fell 9%, Trefis says. The Q3 report is expected around October 29.
Chemists report a dual-functional directing group that lets them build crosslinked ring-shaped peptides, a structure class of interest in drug design.
Researchers found people on GLP-1 medications for weight loss or diabetes reported hair loss and nails lifting off more often than people who never used them.
Loading…